Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

A federal judge has thrown out Amgen’s lawsuit against the state board empowered to set price ceilings on prescription drugs ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Amgen (AMGN) closed at $311.55 in the latest trading session, marking a +1.5% move from the prior day. This move outpaced the S&P 500's daily gain of 0.55%. Elsewhere, the Dow gained 1.01% ...

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...

Shares of Amgen and IBM are posting strong returns Monday morning, sending the Dow Jones Industrial Average into positive territory. The Dow is trading 113 points (0.3%) higher, as shares of Amgen and ...

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $389.00. The company’s ...

After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma ...